Current Report Filing (8-k)
June 04 2021 - 9:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 4, 2021
CELLECTAR
BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
1-36598
|
|
04-3321804
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
100
Campus Drive, Florham Park, New Jersey 07932
(Address of principal executive offices, and zip code)
(608)
441-8120
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, par value $0.00001
|
|
CLRB
|
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
ITEM 7.01
|
REGULATION FD
DISCLOSURE
|
On June 4,
2021, we issued a press release announcing that we presented a poster at the American Society of Clinical Oncology (ASCO) Annual
meeting. In conjunction with the poster presentation, our management will host a KOL call with the lead investigator for our Phase 2 CLOVER-1
study of CLR 131 in patients with relapsed/refractory B-cell hematologic cancers, Dr. Sikander Ailawadhi, M.D. of the Mayo Clinic. A copy
of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 4, 2021
|
CELLECTAR BIOSCIENCES, INC.
|
|
|
|
|
|
By:
|
/s/ Dov Elefant
|
|
|
Name:
|
Dov Elefant
|
|
|
Title:
|
Chief Financial Officer
|
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jul 2023 to Jul 2024